Sosei Heptares Enters R&D Agreements with Oxford University and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders
Sosei Group Company The agreements build on Sosei Heptares’ target identification and validation strategy and translational medicine approach to drug discovery, enabling the company to rapidly prioritize disease-relevant GPCR targets for the structure-based drug design TOKYO and CAMBRIDGE, United Kingdom, 08 Dec. 11, 2022 (GLOBE NEWSWIRE) — Sosei Group Corporation (“the Company”; TSE: 4565), the …